Leveraging the technological accumulation of its university-industry joint laboratory, the company has completed the small-scale sample synthesis and purity determination of two core weight loss and blood sugar lowering APIs—Tirzepatide and Orforglipron—developed by Eli Lilly. It can stably provide API powder, injection formulation debugging, and pilot-scale manufacturing services, officially entering the global high-growth GLP-1 innovative API market and upgrading its products from basic generic drugs to high-end specialty APIs.